Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06339398
Other study ID # 002-2023
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date May 2024
Est. completion date May 31, 2028

Study information

Verified date March 2024
Source Casa di Cura San Raffaele Cassino
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, observational, cohort pilot study of standardize volume of aerobic exercise on changes in BDNF concentration at 4-weeks of exercise training among Parkinson disease patients. Thirty (N=30) participants will be consecutively enrolled and assigned to 2 groups: 1) Extensive Rehabilitation Group (exercise volume: 180 METs-min/week) or 2) Intensive Rehabilitation Group (exercise volume: 1350 METs-min/week). The primary objective is to evaluate the dose-response effects of two different rehabilitation settings, characterized by different workload (measured as energy expenditure), on blood BDNF levels.


Description:

This pilot observational study will evaluate the dose-response relationship between the volume of exercise, measured as METs-minutes/week, of two different rehabilitation settings to quantify the change in BDNF concentration in PD patients. The study will also compare the changes induced by extensive and intensive rehabilitation settings in other neurotrophic factors and peripheral biomarkers, on motor and non-motor symptoms, kinematic parameters of gait, cognitive function, quality of life and the changes in cortical activity assessed with electroencephalogram (EEG) and in brain connectivity by functional magnetic resonance imaging (fMRI).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 30
Est. completion date May 31, 2028
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank - Aged between 30 and 80 years - Disease stage II-III in "ON" phase according to modified Hoehn and Yahr (H&Y) - Having no severe cognitive impairment: - Mini-Mental State Examination-MMSE =24 - Montreal Cognitive Assessment - MoCA = 17/30 - Under stable dopaminergic pharmacological treatment - Motor condition that permits to execute 6-Minutes Walking Test (6MWT) - Willing to participate in the study, understand the procedures and sign the informed consent. Exclusion Criteria: - Diagnosis of neurological disorders not related to Parkinson's disease - Musculoskeletal diseases that could impair gait and execution of exercise program - Presence of known cardiovascular disease that can compromise the performance required by the protocol - Presence of diabetes or other metabolic and endocrine disease - Uncontrolled hypertension (resting blood pressure >150/90 mmHg) - Individuals with orthostatic hypotension and systolic pressure in feet below 100 will be excluded. Orthostatic hypotension (OH) is a reduction in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing. - Hypo- or hyperthyroidism (TSH <0.5 or >5.0 mU/L), abnormal liver function (AST or ALT more than 2 times the upper limit of normal, ULN), alteration of kidney function. - Values of complete blood test out of range and abnormal value clinically significant as per clinical judgment. - Recent use of psychotropic drugs (e.g. anxiolytics, hypnotics, benzodiazepines, antidepressants) in which the dosage was not stable for 28 days before screening - Severe disease (requiring systemic treatment and/or hospitalization) in the last 4 weeks. - Any other clinically significant medical condition, psychiatric condition, drug or alcohol abuse, laboratory evaluation or abnormality that, in the opinion of the investigators, would interfere with the subject's ability to participate in the study. - Beck Depression Inventory II (BDI) score > 28, indicating a severe depression that precludes the ability to exercise. - (Only for women) State of pregnancy. - Other disorders, injuries, diseases or conditions that may interfere with the ability to perform exercises (e.g. history of stroke, breathing problems, traumatic brain injury, orthopaedic injury or neuromuscular disease).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Aerobic exercise
Standardized volume of aerobic exercise, measured as METs-minutes/week

Locations

Country Name City State
Italy San Raffaele Cassino Cassino Frosinone

Sponsors (5)

Lead Sponsor Collaborator
Casa di Cura San Raffaele Cassino IRCCS San Raffaele Roma, San Raffaele Telematic University, University of Rome Tor Vergata, University of Urbino "Carlo Bo"

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) Change from baseline (T0) in blood BDNF concentration 4 weeks
Primary Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) Change from baseline (T0) in blood BDNF concentration 8 weeks
Primary Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) Change from baseline (T0) in blood BDNF concentration 12 weeks
Secondary Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) Change from baseline (T0) in peripheral blood IGF-1 concentration (µg/L) 4 weeks
Secondary Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) Change from baseline (T0) in peripheral blood IGF-1 concentration (µg/L) 8 weeks
Secondary Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) Change from baseline (T0) in peripheral blood IGF-1 concentration (µg/L) 12 weeks
Secondary Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin Change from baseline (T0) in FNDC5/Irisin by peripheral blood samples (ng/mL) 4 weeks
Secondary Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin Change from baseline (T0) in FNDC5/Irisin by peripheral blood samples (ng/mL) 8 weeks
Secondary Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin Change from baseline (T0) in FNDC5/Irisin by peripheral blood samples (ng/mL) 12 weeks
Secondary Change in peripheral biomarker of inflammation Change from baseline (T0) in high sensitivity C-reactive protein (CRP) assessed by peripheral blood samples (mg/L) 4 weeks
Secondary Change in peripheral biomarker of inflammation Change from baseline (T0) in high sensitivity C-reactive protein (CRP) assessed by peripheral blood samples (mg/L) 8 weeks
Secondary Change in peripheral biomarker of inflammation Change from baseline (T0) in high sensitivity C-reactive protein (CRP) assessed by peripheral blood samples (mg/L) 12 weeks
Secondary Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples Change from baseline (T0) in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples 4 weeks
Secondary Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples Change from baseline (T0) in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples 8 weeks
Secondary Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples Change from baseline (T0) in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples 12 weeks
Secondary Change in blood lactate levels assessed using finger-stick capillary blood samples Change from baseline (T0) in blood lactate levels (mM) assessed using finger-stick capillary blood samples 4 weeks
Secondary Change in gut microbial diversity (species diversity %) assessed by next-generation sequencing (NGS) of the V3-V4 region of the 16S rDNA gene Change from baseline (T0) in blood lactate levels (mM) assessed using finger-stick capillary blood samples 4 weeks
Secondary Change in motor symptoms - MDS-UPDRS part II Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II (motor symptoms of daily living). The minimum score on the MDS-UPDRS Part II is 0 and the maximum is 52 with higher scores representing worse motor symptoms of daily living 4 weeks
Secondary Change in motor symptoms - MDS-UPDRS part II Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II (motor symptoms of daily living). The minimum score on the MDS-UPDRS Part II is 0 and the maximum is 52 with higher scores representing worse motor symptoms of daily living 8 weeks
Secondary Change in motor symptoms - MDS-UPDRS part II Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II (motor symptoms of daily living). The minimum score on the MDS-UPDRS Part II is 0 and the maximum is 52 with higher scores representing worse motor symptoms of daily living 12 weeks
Secondary Change in motor symptoms - MDS-UPDRS part III Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (motor examination). The minimum score on the MDS-UPDRS Part III is 0 and the maximum is 132 with higher scores representing worse motor symptoms 4 weeks
Secondary Change in motor symptoms - MDS-UPDRS part III Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (motor examination). The minimum score on the MDS-UPDRS Part III is 0 and the maximum is 132 with higher scores representing worse motor symptoms 8 weeks
Secondary Change in motor symptoms - MDS-UPDRS part III Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (motor examination). The minimum score on the MDS-UPDRS Part III is 0 and the maximum is 132 with higher scores representing worse motor symptoms 12 weeks
Secondary Change in motor symptoms - MDS-UPDRS part IV Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV (motor complication). The minimum score on the MDS-UPDRS Part IV is 0 and the maximum is 24 with higher scores representing worse motor complication 4 weeks
Secondary Change in motor symptoms - MDS-UPDRS part IV Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV (motor complication). The minimum score on the MDS-UPDRS Part IV is 0 and the maximum is 24 with higher scores representing worse motor complication 8 weeks
Secondary Change in motor symptoms - MDS-UPDRS part IV Change from baseline (T0) in Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV (motor complication). The minimum score on the MDS-UPDRS Part IV is 0 and the maximum is 24 with higher scores representing worse motor complication 12 weeks
Secondary Change in movement analysis - stride length Change from baseline (T0) in stride length [m], the distance between two consecutive hell strikes of the same foot evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 4 weeks
Secondary Change in movement analysis - stride length Change from baseline (T0) in stride length [m], the distance between two consecutive hell strikes of the same foot evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 8 weeks
Secondary Change in movement analysis - stride length Change from baseline (T0) in stride length [m], the distance between two consecutive hell strikes of the same foot evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 12 weeks
Secondary Change in movement analysis - cadence Change from baseline (T0) in cadence [steps/min], the number of steps in a minute evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 4 weeks
Secondary Change in movement analysis - cadence Change from baseline (T0) in cadence [steps/min], the number of steps in a minute evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 8 weeks
Secondary Change in movement analysis - cadence Change from baseline (T0) in cadence [steps/min], the number of steps in a minute evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 12 weeks
Secondary Change in movement analysis - propulsion Change from baseline (T0) in propulsion [m/ss], the anterior-posterior acceleration peak during the lower limb swing phase evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 4 weeks
Secondary Change in movement analysis - propulsion Change from baseline (T0) in propulsion [m/ss], the anterior-posterior acceleration peak during the lower limb swing phase evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 8 weeks
Secondary Change in movement analysis - propulsion Change from baseline (T0) in propulsion [m/ss], the anterior-posterior acceleration peak during the lower limb swing phase evaluated by using a wearable device (G-sensor, BTS Bioengineering, Milan) 12 weeks
Secondary Change in movement analysis - Time Up and Go (TUG) Change from baseline (T0) in execution timing of TUG, a reliable and valid test for assessing mobility, balance, walking ability and fall risk, by using a wearable device (G-sensor, BTS Bioengineering, Milan) 4 weeks
Secondary Change in movement analysis - Time Up and Go (TUG) Change from baseline (T0) in execution timing of Time Up and Go (TUG), a reliable and valid test for assessing mobility, balance, walking ability and fall risk, by using a wearable device (G-sensor, BTS Bioengineering, Milan) 8 weeks
Secondary Change in movement analysis - Time Up and Go (TUG) Change from baseline (T0) in execution timing of Time Up and Go (TUG), a reliable and valid test for assessing mobility, balance, walking ability and fall risk, by using a wearable device (G-sensor, BTS Bioengineering, Milan) 12 weeks
Secondary Change in walking capacity Change from baseline (T0) in functional capacity evaluated by 6-minute Walking Test (6MWT), a standardized method to assess the maximal patient's capacity to walk as far as possible (measured in meters) 4 weeks
Secondary Change in walking capacity Change from baseline (T0) in functional capacity evaluated by 6-minute Walking Test (6MWT), a standardized method to assess the maximal patient's capacity to walk as far as possible (measured in meters) 8 weeks
Secondary Change in walking capacity Change from baseline (T0) in functional capacity evaluated by 6-minute Walking Test (6MWT), a standardized method to assess the maximal patient's capacity to walk as far as possible (measured in meters) 12 weeks
Secondary Change in postural instability Change in Berg Balance Scale (BBS), which is a widely used clinical test to assess static and dynamic balance abilities 4 weeks
Secondary Change in postural instability Change in Berg Balance Scale (BBS), which is a widely used clinical test to assess static and dynamic balance abilities 8 weeks
Secondary Change in postural instability Change in Berg Balance Scale (BBS), which is a widely used clinical test to assess static and dynamic balance abilities 12 weeks
Secondary Change in cognitive function - Montreal Cognitive Assessment (MoCA) Change from baseline (T0) in the MoCA. MoCA scores range between 0 and 30, with higher scores representing a better outcome 4 weeks
Secondary Change in cognitive function - Montreal Cognitive Assessment (MoCA) Change from baseline (T0) in the MoCA. MoCA scores range between 0 and 30, with higher scores representing a better outcome 8 weeks
Secondary Change in cognitive function - Montreal Cognitive Assessment (MoCA) Change from baseline (T0) in the MoCA. MoCA scores range between 0 and 30, with higher scores representing a better outcome 12 weeks
Secondary Change in cognitive function - Mini-Mental Examination (MMSE) Change from baseline (T0) in the MMSE. MMSE scores range between 0 and 30, with higher scores representing a better outcome 4 weeks
Secondary Change in cognitive function Change from baseline (T0) in the MMSE. MMSE scores range between 0 and 30, with higher scores representing a better outcome 8 weeks
Secondary Change in cognitive function Change from baseline (T0) in the MMSE. MMSE scores range between 0 and 30, with higher scores representing a better outcome 12 weeks
Secondary Change in cognitive function - Frontal Assessment Battery (FAB) Change from baseline (T0) in the FAB. FAB scores range between 0 and 18, with higher scores representing a better outcome 4 weeks
Secondary Change in cognitive function - Frontal Assessment Battery (FAB) Change from baseline (T0) in the FAB. FAB scores range between 0 and 18, with higher scores representing a better outcome 8 weeks
Secondary Change in cognitive function - Frontal Assessment Battery (FAB) Change from baseline (T0) in the FAB. FAB scores range between 0 and 18, with higher scores representing a better outcome 12 weeks
Secondary Change in severity of depressive symptomatology Change from baseline (T0) in the Beck Depression Inventory-II (BDI-II). 4 weeks
Secondary Change in severity of depressive symptomatology Change from baseline (T0) in the Beck Depression Inventory-II (BDI-II). 8 weeks
Secondary Change in severity of depressive symptomatology Change from baseline (T0) in the Beck Depression Inventory-II (BDI-II). 12 weeks
Secondary Change in non-motor symptoms Change from baseline (T0) in Non-Motor Symptoms Scale (NMSS) in PD 4 weeks
Secondary Change in non-motor symptoms Change from baseline (T0) in Non-Motor Symptoms Scale (NMSS) in PD 8 weeks
Secondary Change in non-motor symptoms Change from baseline (T0) in Non-Motor Symptoms Scale (NMSS) in PD 12 weeks
Secondary Change in motor fluctuations Change from baseline (T0) in wearing OFF episodes will be assessed by Wearing OFF Questionnaire-19 (WOQ-19) 4 weeks
Secondary Change in motor fluctuations Change from baseline (T0) in wearing OFF episodes will be assessed by Wearing OFF Questionnaire-19 (WOQ-19) 8 weeks
Secondary Change in motor fluctuations Change from baseline (T0) in wearing OFF episodes will be assessed by Wearing OFF Questionnaire-19 (WOQ-19) 12 weeks
Secondary Change in quality of life Change from baseline (T0) in will be measured with PDQ-39 questionnaire, which assesses how often PD patients experience difficulties across eight dimensions of daily living (0=never, 4=always). 4 weeks
Secondary Change in quality of life Change from baseline (T0) in will be measured with PDQ-39 questionnaire, which assesses how often PD patients experience difficulties across eight dimensions of daily living (0=never, 4=always). 8 weeks
Secondary Change in quality of life Change from baseline (T0) in will be measured with PDQ-39 questionnaire, which assesses how often PD patients experience difficulties across eight dimensions of daily living (0=never, 4=always). 12 weeks
Secondary Change in cortical activity Change from the baseline (T0) in the cortical activity will be measured with resting-state electroencephalography (rsEEG) 4 weeks
Secondary Change in cortical activity Change from the baseline (T0) in the cortical activity will be measured with resting-state electroencephalography (rsEEG) 12 weeks
Secondary Change in Brain Connectivity Change from the baseline (T0) in brain connectivity through functional magnetic resonance imaging (fMRI). 4 weeks
Secondary Change in Brain Connectivity Change from the baseline (T0) in brain connectivity through functional magnetic resonance imaging (fMRI). 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A